Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

In several phase II-trials encouraging tumour responses rates in advanced metastatic melanoma (stage IV; AJCC-classification) have been reported for the application of biochemotherapy containing interleukin 2. This study was designed to compare the efficacy of therapy with dacarbazine (DTIC) and int...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauschild, A, Garbe, C, Stolz, W, Ellwanger, U, Seiter, S, Dummer, R, Ugurel, S, Sebastian, G, Nashan, D, Linse, R, Achtelik, W, Mohr, P, Kaufmann, R, Fey, M, Ulrich, J, Tilgen, W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363865/
https://www.ncbi.nlm.nih.gov/pubmed/11308250
http://dx.doi.org/10.1054/bjoc.2001.1731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363865/
https://www.ncbi.nlm.nih.gov/pubmed/11308250
http://dx.doi.org/10.1054/bjoc.2001.1731

Ejemplares similares